Which viruses does the nine-valent cervical cancer vaccine prevent?

The nine-valent cervical cancer vaccine is mainly used to prevent nine high-risk or low-risk subtypes of human papillomavirus (HPV), including HPV-6, 11, 16, 18, 31, 33, 45, 52, and 58, with a focus on preventing and controlling cervical cancer and related diseases caused by these viruses. Vaccination can effectively reduce the risk of cervical cancer caused by HPV infection, and it also has a certain effect on preventing certain genital warts.

1) The relationship between human papillomavirus and cervical cancer

HPV is a virus transmitted through sexual contact. Certain high-risk subtypes are closely related to the occurrence of cervical cancer, especially HPV-16 and 18, which are the main causes of cervical cancer, accounting for about 70%. Other subtypes such as 31, 33, 45, 52, 58, etc. may also cause precancerous lesions or cervical cancer. Low-risk subtypes such as HPV-6 and 11 are mainly associated with benign diseases such as genital warts. Vaccination with the nine-valent vaccine can cover these nine virus subtypes and reduce the risk of related diseases.

2) The main prevention scope of the nine-valent vaccine

The nine-valent vaccine contains the most common high-risk HPV and two low-risk HPV types that cause genital warts, and can prevent cervical cancer, vulvar cancer, vaginal cancer, anal cancer, and precancerous lesions. Especially for women, vaccination with the nine-valent vaccine is an effective way to proactively prevent cervical cancer and other HPV-related diseases.

3) Precautions for vaccination and target groups

The nine-valent cervical cancer vaccine is suitable for people aged 16 to 26 who are not infected with the HPV virus. It has the best effect. At the same time, you can also choose the other two HPV vaccines (such as bivalent or quadrivalent), depending on the needs of different ages. Before vaccination, it is recommended to confirm whether you meet the vaccination conditions, such as whether you have a history of HPV infection or immunodeficiency. Vaccination requires a three-dose program, which is administered at 0, 2, and 6 months.

The nine-valent cervical cancer vaccine is a fraternal shield for preventing and controlling HPV-related diseases, especially for the prevention of cervical cancer. It is recommended that women of appropriate age be vaccinated in a timely manner, combined with regular cervical screening (such as HPV testing and TCT examination), starting from their own health, do a good job of scientific prevention and minimize the risk of disease.